{"id":"https://openalex.org/W1978389424","doi":"https://doi.org/10.1007/s00280-013-2361-0","title":"A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors","display_name":"A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors","alternate_titles":[],"publication_year":2013,"publication_date":"2013-12-03","ids":{"openalex":"https://openalex.org/W1978389424","doi":"https://doi.org/10.1007/s00280-013-2361-0","mag":"1978389424","pmid":"https://pubmed.ncbi.nlm.nih.gov/24297683","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3909249"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-013-2361-0","doi":"https://doi.org/10.1007/s00280-013-2361-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-013-2361-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2361-0.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1978389424"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2361-0.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anthony W. Tolcher","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010727781","display_name":"Wendi V. Rodrigueza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Wendi V. Rodrigueza","raw_affiliation_strings":["ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073134832","display_name":"Drew Warren Rasco","orcid":"https://orcid.org/0009-0009-6619-2854","observed_orcids":["https://orcid.org/0009-0009-6619-2854"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Drew W. Rasco","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","institution_ids":["https://openalex.org/I4210119066"]},{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Amita Patnaik","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","institution_ids":["https://openalex.org/I4210119066"]},{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022467575","display_name":"Kyriakos P. Papadopoulos","orcid":"https://orcid.org/0000-0002-0667-2620","observed_orcids":["https://orcid.org/0000-0002-0667-2620"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kyriakos P. Papadopoulos","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","institution_ids":["https://openalex.org/I4210119066"]},{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065184195","display_name":"Alex Amaya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alex Amaya","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","institution_ids":["https://openalex.org/I4210119066"]},{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020794200","display_name":"Timothy David Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Timothy D. Moore","raw_affiliation_strings":["Mid-Ohio Oncology Hematology, Inc., Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mid-Ohio Oncology Hematology, Inc., Columbus, OH, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056498336","display_name":"Shari K. Gaylor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shari K. Gaylor","raw_affiliation_strings":["ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110438741","display_name":"Charles L. Bisgaier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Charles L. Bisgaier","raw_affiliation_strings":["ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020200197","display_name":"Mina Sooch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mina P. Sooch","raw_affiliation_strings":["ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012601023","display_name":"Michael J. Woolliscroft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael J. Woolliscroft","raw_affiliation_strings":["ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011464371","display_name":"Richard Adam Messmann","orcid":"https://orcid.org/0000-0002-2112-0277","observed_orcids":["https://orcid.org/0000-0002-2112-0277"]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Richard A. Messmann","raw_affiliation_strings":["ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., 46701 Commerce Center Dr., Plymouth, MI, 48170, USA","institution_ids":["https://openalex.org/I4210165057"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5011464371"],"corresponding_institution_ids":["https://openalex.org/I4210165057"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":1.733,"has_fulltext":true,"cited_by_count":91,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.84546254,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"73","issue":"2","first_page":"363","last_page":"371"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.8939999938011169,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.8939999938011169,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.05400000140070915,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.0210999995470047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.9039999842643738},{"id":"https://openalex.org/keywords/liposomal-drug-delivery","display_name":"liposomal drug delivery","score":0.640999972820282},{"id":"https://openalex.org/keywords/dna-interference","display_name":"DNA interference","score":0.5640000104904175},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8009999990463257},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9589999914169312},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9039999842643738},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9459999799728394},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8500000238418579},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9079999923706055},{"id":"https://openalex.org/keywords/sarcoma","display_name":"sarcoma","score":0.878000020980835}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8050808906555176},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7197021245956421},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.680374264717102},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6229045391082764},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6122446656227112},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.570950984954834},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.46510252356529236},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.4432833790779114},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.4396460950374603},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4136675298213959},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3630898594856262},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2252849042415619}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004247","descriptor_name":"DNA","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009838","descriptor_name":"Oligodeoxyribonucleotides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019253","descriptor_name":"Proto-Oncogene Proteins c-bcl-2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1007/s00280-013-2361-0","doi":"https://doi.org/10.1007/s00280-013-2361-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-013-2361-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2361-0.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2900850","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3909249","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3909249","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3909249/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemother Pharmacol","raw_type":"Text"},{"id":"pmid:24297683","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24297683","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.783.9344","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.783.9344","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/4b/92/280_2013_Article_2361.PMC3909249.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1007/s00280-013-2361-0","doi":"https://doi.org/10.1007/s00280-013-2361-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-013-2361-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2361-0.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1978389424.pdf","grobid_xml":"https://content.openalex.org/works/W1978389424.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W1499620539","https://openalex.org/W1964963969","https://openalex.org/W1970961784","https://openalex.org/W1971183183","https://openalex.org/W1973289641","https://openalex.org/W1973671033","https://openalex.org/W1978343328","https://openalex.org/W1979113130","https://openalex.org/W1979641337","https://openalex.org/W2022803736","https://openalex.org/W2027728078","https://openalex.org/W2029441191","https://openalex.org/W2035774909","https://openalex.org/W2051209985","https://openalex.org/W2057136548","https://openalex.org/W2061878632","https://openalex.org/W2067014924","https://openalex.org/W2068224949","https://openalex.org/W2081744051","https://openalex.org/W2103450589","https://openalex.org/W2105218405","https://openalex.org/W2113278680","https://openalex.org/W2119316461","https://openalex.org/W2125554513","https://openalex.org/W2126709547","https://openalex.org/W2150680216","https://openalex.org/W2162602733","https://openalex.org/W2166058841","https://openalex.org/W2168632005","https://openalex.org/W2172242534","https://openalex.org/W2328914300","https://openalex.org/W3025713423"],"related_works":["https://openalex.org/W4251983837","https://openalex.org/W2598306974","https://openalex.org/W3186645017","https://openalex.org/W3184807749","https://openalex.org/W1979641337","https://openalex.org/W2890483392","https://openalex.org/W2088367588","https://openalex.org/W2328914300","https://openalex.org/W3044378316"],"abstract_inverted_index":{"PURPOSE:":[0],"Maximum":[1],"tolerated":[2,111,206],"dose,":[3],"safety,":[4],"pharmacokinetics,":[5],"and":[6,55,75,82,108,184,204,225],"pharmacodynamics":[7],"were":[8,34,70,85,94],"assessed":[9],"in":[10,125,137,163,219,223],"this":[11],"phase":[12],"1":[13,62,74],"study":[14,196],"of":[15,21,39,43,65,77,89,100,141,180,189],"PNT2258,":[16,107],"a":[17,22,160],"BCL-2-targeted":[18],"liposomal":[19],"formulation":[20],"24-base":[23],"DNA":[24],"oligonucleotide":[25],"called":[26],"PNT100.":[27],"METHODS:":[28],"Patients":[29],"with":[30,178],"malignant":[31],"solid":[32],"tumors":[33],"assigned":[35],"sequentially":[36],"to":[37,96,127,212,216],"one":[38],"ten":[40],"dose-escalation":[41],"cohorts":[42],"PNT2258":[44,114,128,201,217],"at":[45,119,167,187,207],"1,":[46],"2,":[47],"4,":[48],"8,":[49],"16,":[50],"32,":[51],"64,":[52],"85,":[53],"113,":[54],"150":[56,168,213],"mg/m(2)":[57,123,191],"administered":[58],"intravenously":[59],"on":[60,72,195],"days":[61,73],"through":[63],"5":[64,76],"each":[66,177],"21-day":[67],"cycle.":[68,80],"Pharmacokinetics":[69],"determined":[71],"the":[78,109,130,150,170,208],"first":[79],"Lymphocyte":[81],"platelets":[83],"concentrations":[84],"measured":[86],"for":[87,113,134,197],"evidence":[88,99],"BCL2-targeted":[90],"effect.":[91,102],"CT":[92],"scans":[93],"used":[95],"identify":[97],"radiologic":[98],"anti-tumor":[101,135],"RESULTS:":[103],"Twenty-two":[104],"subjects":[105],"received":[106],"maximum":[110],"dose":[112,172],"was":[115,149,202],"not":[116],"reached.":[117],"Doses":[118],"or":[120,192],"above":[121,129],"32":[122],"resulted":[124,218],"exposure":[126,131],"level":[132],"required":[133],"activity":[136],"preclinical":[138],"xenograft":[139],"testing":[140],"22,377":[142],"ng":[143],"h/ml":[144],"(PK":[145],"analysis":[146],"2012).":[147],"Fatigue":[148],"most":[151],"commonly":[152],"reported":[153],"adverse":[154],"event.":[155],"Dose-limiting":[156],"toxicity,":[157],"manifesting":[158],"as":[159],"transient":[161],"increase":[162],"aspartate":[164],"aminotransferase,":[165],"occurred":[166],"mg/m(2),":[169],"highest":[171],"tested.":[173],"Four":[174],"subjects,":[175],"two":[176],"diagnosis":[179],"non-small-cell":[181],"lung":[182],"cancer":[183],"sarcoma,":[185],"treated":[186],"doses":[188,209],"64":[190],"higher,":[193],"remained":[194],"5-8":[198],"cycles.":[199],"CONCLUSIONS:":[200],"safe":[203],"well":[205],"tested":[210],"up":[211],"mg/m(2).":[214],"Exposure":[215],"clinically":[220],"manageable":[221],"decreases":[222],"lymphocyte":[224],"platelet":[226],"concentrations.":[227]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1978389424","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
